Thursday, 15 October 2026European Markets

BOUVET And DASSAULT SYSTEMES Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - bouvet (bouv.ol) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
bouvet (bouv.ol) kr54.60 4.08% 60.9%
dassault systemes (dsy.pa) €36.13 0.58% 14.06%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. bouvet (bouv.ol)

4.08% forward dividend yield and 60.9% return on equity

bouvet asa provides it and digital communication consultancy services for public and private sector companies in norway, sweden, and internationally. bouvet asa was founded in 1995 and is based in oslo, norway.

earnings per share

as for profitability, bouvet has a trailing twelve months eps of kr3.09.

pe ratio

bouvet has a trailing twelve months price to earnings ratio of 17.67. meaning, the purchaser of the share is investing kr17.67 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 60.9%.

more news about bouvet.

2. dassault systemes (dsy.pa)

0.58% forward dividend yield and 14.06% return on equity

dassault systèmes se provides software solutions and services worldwide. it offers solidworks design software for mechanical and electronic printed circuit board design solutions, product data management, simulation, manufacturing, and technical communication; catia, an engineering and design software for product 3d computer-aided design; geovia for intersection of natural resources, infrastructure and urban planning; and biovia that develops chemicals, biologics, and materials experiences. the company provides simulia that delivers realistic simulation applications; delmia, which enables global industrial operations; 3dvia that provides 3d space planning solutions; and enovia that enables to plan and track the definition of success for customer. in addition, it offers centric plm, a product lifecycle management software solution; 3dexcite, a real-time 3d visualization software; netvibes, which enables organizations to gather, align, and enrich big data; 3dexperience platform that provides organizations a holistic and real-time view of their business activities and ecosystem, as well as connecting people, ideas, data, and solutions together in a single environment; and medidata, a clinical research study software that provides evidences and insights to pharmaceutical, biotech, medical device, and diagnostic companies, as well as academic researchers. it primarily serves companies in the transportation and mobility; industrial equipment; aerospace and defense; high-tech; life sciences and healthcare; energy and materials; home and lifestyle; construction, cities, and territories; consumer packaged goods and retail; marine and offshore; and business services. dassault systèmes se was incorporated in 1981 and is headquartered in vélizy-villacoublay, france.

earnings per share

as for profitability, dassault systemes has a trailing twelve months eps of €0.69.

pe ratio

dassault systemes has a trailing twelve months price to earnings ratio of 52.36. meaning, the purchaser of the share is investing €52.36 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.06%.

more news about dassault systemes.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com